Amendments to the Claims

The listing of claims set forth below will replace all prior versions and listings of claims in the application.

1. (Currently Amended) Dermal A dermal application system, which is a self-adhesive matrix system, eomprising consisting of aminolaevulinic acid (ALA) ALA derivative crystals suspended in a polymer matrix, wherein the ALA derivative erystals are is an aminolaevulinic acid salt or an aminolaevulinic acid ester or a salt thereof, wherein a substantial amount of the crystals of the ALA derivative have a mean diameter of 20 μm to 200 μm, wherein the ALA ester is a compound of the general formula

wherein R1 is an unsubstituted alkyl group, and each of R2 independently from one another represents a hydrogen atom or an unsubstituted alkyl group.

- (Previously Presented) Application system according to claim 1, characterised in that the polymer matrix is water-permeable.
- (Previously Presented) Application system according to claim 1 or 2, characterised in that the polymer matrix is selected from polymers from the group consisting of
 - a) acrylates,
 - b) silicon polymers and
 - c) polyisobutylene.
- (Currently Amended) Application system according to claim 1, characterised in that a substantial amount of the crystals of the ALA derivative have a mean diameter of 30 µm to 190 µm.
- (Currently Amended) Application system according to claim 4, characterised in that a substantial amount of the crystals of the ALA derivative have a mean diameter of 90 μm to 160 μm.

- (Previously Presented) Application system according to claim 1, characterised in that the aminolaevulinic acid derivative is present in a concentration of 1 to 50 wt. % relative to the polymer matrix.
- 7. (Previously Presented) Application system according to claim 4, characterised in that the polymer matrix consists of Eudragit® NE (NE) (ethyl acrylate-methyl methacrylate-copolymerisate) and acetyl tributyl citrate (ATBC) in the weight ratio NE/ATBC of 1:0.5 to 1:2.5, wherein the aminolaevulinic acid derivative is present in a concentration of 1 to 50 wt. % relative to the polymer matrix.
 - 8. (Canceled)
- (Previously Presented) Application system according to claim 1, characterised in that it releases at least 30% of the ALA derivative within 30 minutes.
 - 10-12. (Canceled)
- 13. (Currently Amended) Application system according to <u>claim 1 elaim 10</u>, characterised in that the alkyl group has 1 to 10 carbon atoms.
- 14. (Currently Amended) A dermal application system, which is a self-adhesive matrix system. eemprising consisting of aminolaevulinic acid (ALA) derivative crystals suspended in a polymer matrix, wherein the ALA derivative is an aminolaevulinic acid salt or an aminolaevulinic acid ester or a salt thereof, wherein a substantial amount of the crystals of the ALA derivative have a mean diameter of 20 µm to 200 µm, wherein Application system according to claim 10, characterised in that the ALA derivative is 5-amino levulinic acid methyl ester, 5-amino levulinic acid ethyl ester, 5-amino levulinic acid propyl ester, 5-amino levulinic acid butyl ester, 5-amino levulinic acid propyl ester, 5-amino levulinic acid protyl ester, 5-amino levulinic acid butyl ester, 5-amino levulinic acid protyl ester, 5-amino levulinic acid butyl ester, 5-amino levulinic acid butyl ester, 5-amino levulinic acid protyl ester, 5-amino levulinic acid butyl ester, 5-amino lev

15-22. (Canceled)